The Impact of Inhaled Treprostinil on Dyspnea and Exercise Intolerance in Mild COPD; a Pilot and Feasibility Trial
Status: Recruiting
Location: See location...
Intervention Type: Drug, Combination product
Study Type: Interventional
Study Phase: Phase 2
SUMMARY
The goal of this clinical trial is to evaluate the impact of inhaled Treprostinil on breathlessness and low exercise capacity in patients living with mild chronic obstructive pulmonary disease. Participants will be asked to: * Perform lung function and exercise tests * Have ultrasound of their heart * Have CT images of their lungs * Visit the lab on 5 different occasions (plus one visit to the CT imaging clinic) The researchers will compare the effectiveness and feasibility of inhaled Treprostinil to improve breathlessness upon exertion and exercise capacity
Eligibility
Participation Requirements
Sex: All
Minimum Age: 50
Maximum Age: 85
Healthy Volunteers: f
View:
• Patients with mild COPD (defined as having a postbronchodilator FEV1/FVC ratio \<0.70 and FEV1 ≥ 80% predicted
Locations
Other Locations
Canada
Clinical Physiology Laboratory
RECRUITING
Edmonton
Contact Information
Primary
Desi Fuhr, MSc
fuhr@ualberta.ca
7804921121
Backup
Andrew W D'Souza, PhD
awdsouza@ualberta.ca
7804928027
Time Frame
Start Date: 2025-06-05
Estimated Completion Date: 2026-12-31
Participants
Target number of participants: 20
Treatments
Placebo_comparator: Placebo
Participants will inhale placebo (room air) from the Tyvaso Inhalation System Ultrasonic nebulizer
Experimental: Treprostinil 36 mcg
Participants will inhale 36 mcg of Treprostinil from the Tyvaso Inhalation System Ultrasonic nebulizer
Experimental: Treprostinil 78 mcg
Participants will inhale 78 mcg of Treprostinil from the Tyvaso Inhalation System Ultrasonic nebulizer
Related Therapeutic Areas
Sponsors
Leads: University of Alberta